Innovasis faces a new legal battle as patent infringement claims have reached $50 million. This marks one of the most important legal challenges for the spinal implant manufacturer. The company recently paid $12 million to settle a case where they gave improper payments to seventeen orthopedic and neurosurgeons from 2014 to 2022.
RSB Spine LLC leads this legal fight and claims Innovasis violated US Patent No. 9,713,537. The patent relates to intervertebral body fusion devices that treat degenerative disk disease. The lawsuit also claims trade secret theft, which makes the company’s position even more difficult. The case revolves around a bone-plate stabilization system that plays a vital role in spinal injury repairs. This technology’s importance shows why there’s so much at stake financially and technically.
Innovasis faces a $50M patent infringement lawsuit
RSB Spine LLC has taken legal action against medical device maker Innovasis Inc. to protect its spinal implant technology patents. The company filed the lawsuit in the U.S. District Court for the District of Utah on April 10, 2024. This move is part of RSB Spine’s strategy to enforce its intellectual property rights in the medical device sector.
Court papers show that Innovasis turned down several chances to get a license from RSB Spine for technology under U.S. Patent No. 9,713,537. The patent covers intervertebral body fusion devices that treat degenerative disk disease and bone-plate stabilization systems for spinal injury repair.
The dispute traces back to 2018 when RSB Spine first reached out to Innovasis. The lawsuit states that RSB Spine sent Innovasis a notice letter that year. The letter pointed out how the company’s Ax Stand-Alone ALIF System might have broken at least two patent claims. This first contact led to years of failed attempts to solve the issue outside the court.
After the first notice, Innovasis showed “its unwillingness to be involved in meaningful licensing discussions with RSB”. RSB Spine didn’t give up and sent three more similar letters in 2021 and 2023. Innovasis resisted these attempts, too.
RSB Spine received this patent in 2017. The company has been quick to protect its intellectual property rights since then. It has sued other device makers in the orthopedic field. These legal actions show RSB’s dedication to defending its patent portfolio.
RSB Spine knows how to win these battles. The company got £9.53 million (approximately $12 million) in a patent case against DePuy Synthes in 2022. This win likely gave RSBthe confidence to pursue its claims against Innovasis.
The alleged infringement centers on how Innovasis uses bone screws in its products. RSB claims these parts help with bone plate stabilization in a way that copies their patented technology. The ‘537 patent covers a bone-plate stabilization system for spinal injury repairs.
Medical device companies often face patent infringement cases. New technologies build on existing designs step by step. These overlapping developments lead to complex property disputes. Courts must analyze and compare the patented invention with the product that might copy it.
RSB Spine wants a jury trial and compensation for Innovasis’ alleged patent infringement. Court documents don’t specify how much money RSB seeks. Cases like this can result in big financial penalties.
A court win for RSB could mean more than just money for Innovasis. The court might stop Innovasis from selling products that copy the patent. This would hurt the company’s product line and market position.
This patent fight adds to Innovasis’ legal troubles. The company faces other court battles at the same time, making this a tough period.
The case shows how medical device companies struggle to balance progress with patent rights. This challenge creates many lawsuits in this competitive and innovative field.
What are the claims against Innovasis?
The legal battle centers on claims that Innovasis used RSB’s protected technology in their medical devices without permission. The lawsuit presents several claims showing this wasn’t just an accidental overlap of technology. RSB believes Innovasis knew what they were doing.
Alleged use of patented spinal implant technology
RSB Spine claims Innovasis used its patented spinal implant technology without proper authorization. The technology helps treat degenerative disk disease through intervertebral body fusion devices. These medical implants need heavy investment in research and development, which makes protecting them crucial for patent holders.
The disputed technology revolves around a bone-plate stabilization system that repairs spinal injuries. This system marks a breakthrough in spinal fusion procedures. Doctors can now achieve better stability during healing. Medical device companies invest heavily in their designs and technologies, making these systems vital to their business.
RSB Spine points to Innovasis’s bone screw stabilization systems as direct copies of their patented elements. These patent disputes need detailed technical comparisons between original and copied products. Innovasis could face big financial penalties if found guilty. They might have to pay both damages and royalties.
Refusal to license from RSB Spine LLC
RSB Spine’s legal complaint highlights how Innovasis repeatedly turned down licensing agreements. Court papers show Innovasis wouldn’t negotiate a licensing deal for the protected technology. RSB uses this refusal to show Innovasis’s intentions.
The company’s history goes back several years. RSB Spine first wrote to Innovasis in 2018. They pointed out how Innovasis’s Ax Stand-Alone ALIF System copied at least two patent claims. Innovasis brushed off this notice and three more were sent in 2021 and 2023.
RSB Spine tried to solve this outside the court for five years. They sent multiple notices, showing they really wanted to reach an agreement before suing. Innovasis kept rejecting these attempts, which now strengthens RSB’s case.
Violation of US Patent No. 9,713,537
US Patent No. 9,713,537, issued to RSB Spine in 2017, sits at the heart of this dispute. This patent protects a bone-plate stabilization system for spinal injury repair. The patent describes “a base plate configured to fit primarily between an anterior portion of a first bone’s lip osteophyte and an anterior portion of a second, adjacent bone’s lip osteophyte” with “a plurality of bone screws configured to fit in respective bone screw holes in the base plate to secure the base plate”.
RSB Spine says Innovasis’s products, especially those with bone screws for plate stabilization, break this patent. RSB can show specific comparisons between their patent and Innovasis’s products to prove their case.
The ‘537 patent has won before in court. RSB Spine received £9.53 million (about $12 million) when they sued DePuy Synthes, part of Johnson & Johnson’s orthopedics division, in 2022. This win shows both the patent’s value and RSB’s commitment to protecting it.
RSB Spine wants a jury trial and compensation for patent infringement. They’ve fought this battle before and likely know how to prove their case. They’ll probably use side-by-side technical comparisons and expert witnesses.
How did Innovasis allegedly infringe the patent?
RSB Spine’s infringement allegations are based on the technical specifications of Innovasis’s spinal implant products. The court documents show detailed comparisons between Innovasis’s devices and RSB’s patented technology. These documents point to specific design elements that allegedly violate intellectual property protections.
Use of bone screw stabilization system
RSB’s allegations center on Innovasis’s bone screw stabilization system that closely matches RSB’s patented technology. The lawsuit specifically targets Innovasis’s Ax® Stand-Alone ALIF System. This system works as an intervertebral body fusion device that stabilizes spinal segments, promotes fusion, restricts motion, and decreases pain.
Court filings reveal how Innovasis allegedly copied RSB’s patented bone-plate stabilization system. RSB claims that Innovasis’s product uses bone screws to help with bone plate stabilization in a way similar to RSB’s patented approach. The system includes:
- A base plate with a top surface, first and second ends, bottom surface, and multiple bone screw holes
- Placement between the anterior portions of adjacent vertebral bones’ lip osteophytes
- A configuration designed to bear weight while sharing the load with bone graft material
- Multiple bone screws that fit into the bone screw holes at specific angles
Court documents state that “Innovasis has infringed directly and indirectly, literally and under the doctrine of equivalents, at least claims 1, 14, and 21 of the ‘537 Patent by making, using, selling, and/or offering for sale the Accused Product”.
Similar to RSB’s intervertebral fusion device
The lawsuit provides extensive technical comparisons between the patented technology and Innovasis’s product. The Ax® Stand-Alone ALIF System comes with a titanium faceplate and an Invibio PEEK-OPTIMA HA Enhanced body. The HA-enhanced PEEK combines smoothly with osteoconductive hydroxyapatite.
RSB’s patent (US No. 9,713,537) covers an intervertebral body fusion device that treats degenerative disk disease. The alleged similarities include several critical design elements:
- The configuration of bone screw holes that extend from the base plate’s top surface
- The orientation of bone screws in an anterior-posterior direction
- The specific placement of the device between vertebral bones
The lawsuit emphasizes that “the Accused Product has a first of the bone screw holes configured to receive a first of the bone screws that extends at least partially from the top surface of a base plate and opens at least partially toward the side surface of a first of the vertebral bones”. This technical specification matches the language in RSB’s patent claims exactly.
Timeline of product development and release
This alleged infringement story spans several years. RSB got US Patent No. 9,713,537 in 2017, which protected their intervertebral fusion device technology. RSB then spotted potential infringement and started communicating with Innovasis.
RSB sent their original notice letter to Innovasis on July 5, 2018. The letter identified how the company’s Ax Stand-Alone ALIF System allegedly infringed at least two patent claims. Innovasis showed no interest in involving itself in meaningful licensing discussions with RSB.
RSB tried to resolve the dispute without going to court. They sent three more letters in 2021 and 2023, but Innovasis allegedly resisted all attempts. During this time, Innovasis kept manufacturing and distributing the products that allegedly infringed the patent.
RSB alleges that Innovasis knowingly led others to infringe the patent “by, among other things, actively aiding and abetting others to infringe with specific intent or willful blindness”. These actions included advertising and distributing the Accused Product while providing instructional materials, training, and services.
The lawsuit states that since July 5, 2018, Innovasis has known about the ‘537 Patent and understood that its actions were causing infringement. This extended period of alleged knowing infringement plays a crucial role in RSB’s legal argument and could affect both liability and damages calculations.
Who are the key players in the lawsuit?
The legal battle between RSB Spine and Innovasis features several distinct parties, each playing unique roles in this patent dispute. This case stands as one of the most important intellectual property conflicts in the medical device industry, with major financial stakes for both companies.
RSB Spine LLC as plaintiff
RSB Spine LLC operates as a Delaware-based limited liability company with its main office in Wooster, Ohio. The company started the legal proceedings against Innovasis as the owner of U.S. Patent No. 9,713,537. RSB has built a reputation as a fierce defender of its intellectual property rights. The company has filed many similar lawsuits against other medical device makers in the orthopedic field.
RSB’s legal approach shows how seriously they take protecting their patent portfolio. This lawsuit against Innovasis fits into their broader strategy of patent enforcement. The company saw a big win in 2022 against DePuy Synthes, walking away with £9.53 million (about $12 million).
RSB Spine has asked for a jury trial in this case, which shows their confidence in proving infringement. The company sent multiple notice letters to Innovasis between 2018 and 2023, proving its commitment to protecting its patent rights.
Innovasis Inc. as a defendant
Innovasis Inc. faces this high-stakes patent battle as the defendant. The Utah-based company runs its main operations from Salt Lake City. They work as a medical device company that “researches, develops, manufactures, and markets spinal implant devices and related products nationwide”.
Court documents describe the medical device market as “very competitive”, which explains the commercial tensions behind this legal fight. Innovasis makes and sells various spinal therapy products, with a focus on anterior lumbar interbody fusion (ALIF) devices.
Innovasis also makes products for other medical device companies like Ortho Development Corporation and Reliance Medical Systems. This broader manufacturing role means any court ruling against them could have bigger effects on the industry.
Michael English, Innovasis’s former president who worked there from February 2014 until May 2019, was named in related legal proceedings but left the case in December 2023. His involvement adds another layer to Innovasis’s legal challenges.
A federal court in Utah is overseeing the case
The U.S. District Court for the District of Utah handles this litigation, filed as case number 2:2024cv00264 on April 10, 2024. The court’s power comes from 28 U.S.C. 1331 and 1338(a), which covers patent-related cases.
Judge David Barlow leads the case, while Judge Dustin B. Pead serves as the referring judge. Utah makes sense as the venue under 28 U.S.C. 1400(b) since Innovasis is a Utah company that has “purposely used the privileges and benefits of Utah’s laws”.
The court can issue protective orders and manage discovery processes, as shown by motions about subpoenas and depositions. The court noted it “must limit discovery’s frequency or extent” if the requested information seems “unreasonably repetitive”.
This patent infringement case represents a crucial matter for Utah’s federal court. It deals with complex intellectual property issues in specialized medical devices. The court’s decisions will likely set important examples for patent enforcement in the spinal implant industry.
What legal precedents and statutes are involved?
Legal statutes and precedents are the foundations of RSB Spine’s claims against Innovasis. This creates a complex legal landscape that will shape the outcome of this high-stakes patent dispute.
Patent Act and intellectual property law
The Patent Act sets the legal framework for this case, particularly 35 U.S.C. § 271, which defines patent infringement. The statute states that anyone who “makes, uses, offers to sell, or sells any patented invention” without permission infringes the patent. The case will likely draw from landmark patent decisions like Apple Inc. v. Samsung Electronics Co., where Apple won over £0.79 billion in damages for patent infringement.
Markman v. Westview Instruments, Inc. made it clear that judges, not juries, interpret patent claims as a matter of law. This 26-year-old precedent means the judge in the Innovasis case will decide the scope of RSB’s patent claims before the jury looks at infringement.
The doctrine of equivalents, mentioned in RSB’s complaint, allows courts to find infringement even when products don’t exactly violate patent claims but work in basically the same way.
Previous Innovasis legal history
Innovasis faced major legal challenges before this patent dispute. The company and two executives paid $12 million to settle claims that they violated the Anti-Kickback Statute from 2014 to 2022. This settlement addressed allegations that Innovasis gave improper payments to seventeen orthopedic surgeons and neurosurgeons to encourage them to use Innovasis spinal implants.
These improper payments included “consulting fees, intellectual property acquisition and licensing fees, registry payments and performance shares in Innovasis, as well as travel to a luxury ski resort, lavish dinners and holiday parties”. Innovasis reportedly paid some physicians for consulting work they never did or for intellectual property they never used.
False Claims Act and Anti-Kickback Statute context
The False Claims Act helps fight healthcare fraud by holding companies responsible when they knowingly submit false claims to the government. The earlier Innovasis settlement came from a qui tam case that former Regional Sales Director Robert Richardson filed under the Act’s whistleblower provisions.
The Anti-Kickback Statute makes it illegal to “offer or pay anything of value to induce referrals of items or services covered by Medicare and other federally funded programs”. This law keeps financial incentives from affecting medical decisions. Breaking this law can lead to civil and criminal penalties, including big fines and possible exclusion from federal healthcare programs.
These previous legal issues give valuable context about Innovasis’s broader legal challenges in the medical device industry, even though they’re separate from the current patent case.
What role did whistleblowers and former employees play?
Former employees and whistleblowers have become key players in Innovasis’s legal challenges by revealing alleged wrongdoing inside the company.
Robert Richardson’s earlier qui tam case
Robert Richardson, Innovasis’s former Regional Sales Director, filed a whistleblower lawsuit under the qui tam provisions of the False Claims Act. The government used this legal action to break down Innovasis’s business practices regarding payments to spine surgeons. Richardson’s position in the company gave great insights when he found a “questionable intellectual property agreement” after getting a voice mail message from an angry surgeon.” The surgeon claimed he hadn’t received payment for a product that was neither developed nor marketed.
The contract Richardson identified was worth £198,540.03 over two years for alleged intellectual property that “did not lead to anything of substance”. His efforts as a whistleblower paid off well – he received about £1.75 million as his share of the settlement.
Michael English’s alleged threats and actions
Michael English led Innovasis as president from February 2014 until May 2019. He took a different path when leaving the company. English tried to get a severance package of about £1,588,320.23 after announcing his resignation. Court documents show he directly threatened to “institute a qui tam action against the company” if Innovasis didn’t meet his demands.
English allegedly had his assistant collect many Innovasis documents, which he copied before resigning. Innovasis states these materials had “Confidential, Proprietary, and Trade Secret Information” that English took after his departure. The company later claimed English “inappropriately provided” this information to someone else who then filed legal action against Innovasis.
Impact of internal knowledge on legal exposure
Former employees’ insider knowledge created major legal risks for Innovasis. Their deep understanding of company operations and access to documents helped expose alleged misconduct.
The Employment Rights Act 1996 protects “workers,” including former employees, from retaliation when they blow the whistle. People with inside information about potential fraud can get 15-30% ofthe money collected from successful lawsuit settlements.
These insider-driven legal actions show how former employees who know about questionable practices can bring serious legal and financial problems to medical device companies working in heavily regulated industries.
Conclusion
Legal Battle Implications
The Innovasis patent infringement case poses a major challenge for the medical device manufacturer. This comes right after their $12 million settlement for Anti-Kickback Statute violations. RSB Spine’s aggressive stance on patent enforcement shows how much companies value intellectual property protection in the competitive medical device market. Their persistent attempts at licensing negotiations since 2018 make this clear.
Patent disputes are common throughout the medical technology sector. This case stands out because of its technical focus on bone screw configurations and intervertebral fusion device designs. These technical details will shape the outcome as the court gets into whether Innovasis products violate RSB’s patented technology.
Both companies face serious financial stakes. RSB Spine won a substantial $12 million judgment against DePuy Synthes in a similar case, which might set a precedent for damages. Innovasis could face more than just financial penalties – they might be restricted from manufacturing and selling their core product lines if found liable.
Whistleblowers and former employees have played a vital role in revealing alleged misconduct at Innovasis. Their inside knowledge gave authorities concrete evidence about questionable business practices. This raises serious concerns about the company’s oversight and compliance standards.
Medical device manufacturers need to strike a balance between innovation and respecting intellectual property rights. Companies working on spinal implant technologies must develop new medical solutions while navigating complex patent rules. This requires thorough research before product development and proactive licensing talks when potential conflicts surface.
The Utah federal court’s ruling will likely create important precedents for patent enforcement in the spinal implant industry. The case shows how legal challenges can quickly pile up for companies in highly regulated medical sectors, especially when insiders expose alleged wrongdoing.
This patent dispute reminds us how intellectual property shapes medical innovation. The outcome could reshape how companies develop technology, handle licensing talks, and manage corporate compliance in this specialized field.
FAQs
1. What is the main issue in the Innovasis lawsuit?
The main issue is a $50 million patent infringement claim filed by RSB Spine LLC against Innovasis Inc. RSB Spine alleges that Innovasis violated its patent on intervertebral body fusion devices used to treat degenerative disk disease.
2. What specific technology is at the center of the patent dispute?
The disputed technology involves a bone-plate stabilization system designed for spinal injury repair. RSB Spine claims Innovasis used this patented technology in their bone screw stabilization systems without proper authorization.
3. How long has this legal dispute been ongoing?
The dispute dates back to 2018 when RSB Spine first contacted Innovasis about potential patent infringement. RSB Spine sent multiple notices between 2018 and 2023 before filing the lawsuit in 2024.
4. What are the potential consequences for Innovasis if they lose the case?
If Innovasis loses, they could face significant financial penalties, potentially up to $50 million in damages. Additionally, they may be barred from selling the allegedly infringing products, which could impact their market position.
5. Has Innovasis faced other legal challenges recently?
Yes, before this patent dispute, Innovasis and two executives agreed to pay $12 million to settle allegations of violating the Anti-Kickback Statute between 2014 and 2022. This involved claims of providing improper payments to surgeons to induce them to use Innovasis spinal implants.